Bicara Therapeutics (BCAX) shares fell 44% in recent trading Friday, a day after the company said that its latest clinical trial for a potential head and neck cancer treatment has yet to reach median overall survival.
The Phase 1/1b trial evaluates ficerafusp alfa in combination with pembrolizumab in patients with first line recurrent/metastatic head and neck squamous cell carcinoma, the company said.
Intraday volume topped 5.49 million shares versus the daily average of about 588,000.
Price: 8.70, Change: -6.96, Percent Change: -44.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.